Literature DB >> 19757082

Lipidic systems for in vivo siRNA delivery.

Sherry Y Wu1, Nigel A J McMillan.   

Abstract

The ability of small-interfering RNA (siRNA) to silence specific target genes not only offers a tool to study gene function but also represents a novel approach for the treatment of various human diseases. Its clinical use, however, has been severely hampered by the lack of delivery of these molecules to target cell populations in vivo due to their instability, inefficient cell entry, and poor pharmacokinetic profile. Various delivery vectors including liposomes, polymers, and nanoparticles have thus been developed in order to circumvent these problems. This review presents a comprehensive overview of the barriers and recent progress for both local and systemic delivery of therapeutic siRNA using lipidic vectors. Different strategies for formulating these siRNA-loaded lipid particles as well as the general concern about their safe use in vivo will also be discussed. Finally, current advances in the targeted delivery of siRNA and their impacts on the field of RNA interference (RNAi)-based therapy will be presented.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19757082      PMCID: PMC2782074          DOI: 10.1208/s12248-009-9140-1

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  111 in total

Review 1.  Lipoplex-mediated delivery of nucleic acids: factors affecting in vivo transfection.

Authors:  Crispin R Dass
Journal:  J Mol Med (Berl)       Date:  2004-06-23       Impact factor: 4.599

2.  Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7.

Authors:  Veit Hornung; Margit Guenthner-Biller; Carole Bourquin; Andrea Ablasser; Martin Schlee; Satoshi Uematsu; Anne Noronha; Muthiah Manoharan; Shizuo Akira; Antonin de Fougerolles; Stefan Endres; Gunther Hartmann
Journal:  Nat Med       Date:  2005-02-20       Impact factor: 53.440

3.  Nonviral delivery platform for therapeutic RNAi: pegylated siRNA/cationic liposome complexes for targeting of the proto-oncogene bcl-2.

Authors:  Sabrina Höbel; Achim Aigner
Journal:  Future Oncol       Date:  2009-02       Impact factor: 3.404

4.  Laboratory and clinical studies in support of cystic fibrosis gene therapy using pCMV-CFTR-DOTAP.

Authors:  G McLachlan; L P Ho; H Davidson-Smith; J Samways; H Davidson; B J Stevenson; A D Carothers; E W Alton; P G Middleton; S N Smith; G Kallmeyer; U Michaelis; S Seeber; K Naujoks; A P Greening; J A Innes; J R Dorin; D J Porteous
Journal:  Gene Ther       Date:  1996-12       Impact factor: 5.250

5.  Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes.

Authors:  S Dokka; D Toledo; X Shi; V Castranova; Y Rojanasakul
Journal:  Pharm Res       Date:  2000-05       Impact factor: 4.200

6.  Full motor recovery despite striatal neuron loss and formation of irreversible amyloid-like inclusions in a conditional mouse model of Huntington's disease.

Authors:  Miguel Díaz-Hernández; Jesús Torres-Peraza; Alejandro Salvatori-Abarca; María A Morán; Pilar Gómez-Ramos; Jordi Alberch; José J Lucas
Journal:  J Neurosci       Date:  2005-10-19       Impact factor: 6.167

7.  Targeting ECM-integrin interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imaging model.

Authors:  Kristen Bisanz; Jie Yu; Magnus Edlund; Bill Spohn; Mien-Chie Hung; Leland W K Chung; Chia-Ling Hsieh
Journal:  Mol Ther       Date:  2005-10       Impact factor: 11.454

8.  RNA interference targeting transforming growth factor-beta type II receptor suppresses ocular inflammation and fibrosis.

Authors:  Hiroshi Nakamura; Shahid S Siddiqui; Xiang Shen; Asrar B Malik; Jose S Pulido; Nalin M Kumar; Beatrice Y J T Yue
Journal:  Mol Vis       Date:  2004-10-04       Impact factor: 2.367

9.  Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles.

Authors:  Suzie H Pun; Frederik Tack; Nathalie C Bellocq; Jianjun Cheng; Brendan H Grubbs; Gregory S Jensen; Mark E Davis; Marcus Brewster; Michel Janicot; Boudewijn Janssens; Wim Floren; Annette Bakker
Journal:  Cancer Biol Ther       Date:  2004-07-09       Impact factor: 4.742

10.  Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque.

Authors:  Bao-jian Li; Qingquan Tang; Du Cheng; Chuan Qin; Frank Y Xie; Qiang Wei; Jun Xu; Yijia Liu; Bo-jian Zheng; Martin C Woodle; Nanshan Zhong; Patrick Y Lu
Journal:  Nat Med       Date:  2005-08-21       Impact factor: 53.440

View more
  55 in total

1.  A cell-penetrating helical polymer for siRNA delivery to mammalian cells.

Authors:  Nathan P Gabrielson; Hua Lu; Lichen Yin; Kyung Hoon Kim; Jianjun Cheng
Journal:  Mol Ther       Date:  2012-05-29       Impact factor: 11.454

Review 2.  Technologies for controlled, local delivery of siRNA.

Authors:  Samantha M Sarett; Christopher E Nelson; Craig L Duvall
Journal:  J Control Release       Date:  2015-11-28       Impact factor: 9.776

3.  Sustained local delivery of siRNA from an injectable scaffold.

Authors:  Christopher E Nelson; Mukesh K Gupta; Elizabeth J Adolph; Joshua M Shannon; Scott A Guelcher; Craig L Duvall
Journal:  Biomaterials       Date:  2011-11-05       Impact factor: 12.479

4.  Microfluidic assembly of lipid-based oligonucleotide nanoparticles.

Authors:  Bo Yu; Jing Zhu; Weiming Xue; Yun Wu; Xiaomeng Huang; L James Lee; Robert J Lee
Journal:  Anticancer Res       Date:  2011-03       Impact factor: 2.480

5.  Conjugation of palmitic acid improves potency and longevity of siRNA delivered via endosomolytic polymer nanoparticles.

Authors:  Samantha M Sarett; Kameron V Kilchrist; Martina Miteva; Craig L Duvall
Journal:  J Biomed Mater Res A       Date:  2015-02-27       Impact factor: 4.396

6.  Relationships between liposome properties, cell membrane binding, intracellular processing, and intracellular bioavailability.

Authors:  Yinghuan Li; Jie Wang; Yue Gao; Jiabi Zhu; M Guillaume Wientjes; Jessie L-S Au
Journal:  AAPS J       Date:  2011-09-10       Impact factor: 4.009

Review 7.  Novel siRNA delivery strategy: a new "strand" in CNS translational medicine?

Authors:  Lisa Gherardini; Giuseppe Bardi; Mariangela Gennaro; Tommaso Pizzorusso
Journal:  Cell Mol Life Sci       Date:  2013-03-19       Impact factor: 9.261

Review 8.  Technologies for investigating the physiological barriers to efficient lipid nanoparticle-siRNA delivery.

Authors:  Bin Shi; Marc Abrams
Journal:  J Histochem Cytochem       Date:  2013-03-14       Impact factor: 2.479

Review 9.  RNA therapeutics targeting osteoclast-mediated excessive bone resorption.

Authors:  Yuwei Wang; David W Grainger
Journal:  Adv Drug Deliv Rev       Date:  2011-09-10       Impact factor: 15.470

10.  A secretagogue-small interfering RNA conjugate confers resistance to cytotoxicity in a cell model of Sjögren's syndrome.

Authors:  Kaleb M Pauley; Adrienne E Gauna; Irina I Grichtchenko; Edward K L Chan; Seunghee Cha
Journal:  Arthritis Rheum       Date:  2011-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.